Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Remus Pharmaceuticals Ltd
Quarter-by-quarter operating performance
Financials of Remus Pharmaceuticals Ltd
Annual income statement trend
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales + | 213 | 620 | 854 |
| Expenses + | 184 | 575 | 797 |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14% | 7% | 7% |
| Other Income + | 3 | 5 | 7 |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| Profit before tax | 30 | 47 | 59 |
| Tax % | 20% | 19% | 22% |
| Net Profit + | 24 | 38 | 46 |
| EPS in Rs | 17.69 | 24.64 | 31.39 |
| Dividend Payout % | 4% | 3% | 2% |
Financials of Remus Pharmaceuticals Ltd
Capital structure and asset base
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| Borrowings + | 14 | 23 | 27 |
| Other Liabilities + | 161 | 154 | 201 |
| Total Liabilities | 333 | 433 | 579 |
| Fixed Assets + | 14 | 16 | 18 |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| Other Assets + | 215 | 231 | 277 |
| Total Assets | 333 | 433 | 579 |
Financials of Remus Pharmaceuticals Ltd
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity + | 1 | 7 | 18 |
| Cash from Investing Activity + | -25 | -11 | -15 |
| Cash from Financing Activity + | 28 | 6 | 1 |
| Net Cash Flow | 4 | 3 | 5 |
| Free Cash Flow | -11 | 3 | 4 |
| CFO/OP | 25% | 32% | 49% |
Financials of Remus Pharmaceuticals Ltd
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 57 |
| ROCE % | 20% | 17% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…